All the news Showing 10 of 135 articles from: Interferon-free regimensGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Gilead expects big increase in Europeans treated with hep C drug Reuters / 11 February 2015 Sales of Sovaldi, New Gilead Hepatitis C Drug, Soar to $10.3 Billion New York Times / 05 February 2015 Merck says hepatitis C drugs to lose breakthrough status Reuters / 05 February 2015 European Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for the Treatment of Chronic Hepatitis C AbbVie press release / 16 January 2015 Novartis bids final farewell to HCV with Debiopharm exit Pharma Times / 13 January 2015 Express Scripts explains exclusive AbbVie hepatitis C prescribing deal Manual Items / 07 January 2015 US FDA approves AbbVie hepatitis C drug, costs $83319 for 12 weeks Reuters / 20 December 2014 CHMP Grants Positive Opinions of AbbVie’s VIEKIRAX™ (ombitasvir/paritaprevir/ritonavir) + EXVIERA™ (dasabuvir) for the Treatment of Chronic Hepatitis C in Europe AbbVie press release / 21 November 2014 Two studies show promise for 8-week treatment with GS-5816 Healio Hepatology / 17 November 2014 Phase 3 UNITY Trials Demonstrate High Cure Rates for Investigational, All-Oral Daclatasvir TRIO Fixed-Dose Combination in Genotype 1 Hepatitis C Patients, Including Those with Cirrhosis Bristol-Myers Squibb press release / 10 November 2014 ← Prev1...23456...14Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive